Average waist circumference, BMI, and HbA1c also decreased more in the semaglutide group
Both formats contain the same active ingredient semaglutide and produce similar results
Recent FDA approvals and indications for products containing semaglutide include the reduction of cardiovascular risk in patients with type 2 diabetes and body weight reduction for obesity
The FDA has approved semaglutide for chronic weight management under the brand name Wegovy
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, improve glycemic control and are associated with weight loss, but the impact of weight loss on major adverse cardiovascular events (MACE) when taking semaglutide is not fully understood
Secondly, the glycine corresponding to proglucagon (108) was found to serve as a substrate for amidation of the C-terminal arginine resulting in the equally potent GLP-1 (736) amide